Profound Medical Corp
Change company Symbol lookup
Select an option...
PROF Profound Medical Corp
ELGXQ Endologix Inc
ONOV BioNovelus Inc
ATO Atmos Energy Corp
NMS Nuveen Minnesota Quality Municipal Income Fund
INVVY Indivior PLC
OSUR OraSure Technologies Inc
QUOT Quotient Technology Inc
DUK Duke Energy Corp
WAFD Washington Federal Inc
Go

Health Care : Health Care Equipment & Supplies | Small Cap Growth
Based in Canada
Company profile

Profound Medical Corp. is a commercial-stage medical device company. focused on customizable, incision-free therapies which combine real-time magnetic resonance imaging (MRI), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue. The Company’s products include TULSA-PRO System and SONALLEVE. The TULSA-PRO is used to ablate benign or malignant prostate tissue in patients with a variety of prostate diseases. Prostate diseases include prostate cancer and benign prostatic hyperlasia (BPH). Prostate cancer is one of the common types of cancer affecting men. TULSA-PRO and SONALLEVE share the common technological concept of using MRI to enable visualization of the surgeon desired tissue in real time. Both products also use thermal ultrasound technology to heat and ablate tissue.

Price
Delayed
$16.67
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)

Today's volume of 0 shares is on pace to be much lighter than PROF's 10-day average volume of 137,048 shares.

0

Nio's stock dives after Goldman Sachs turns bearish on valuation concerns

9:14 am ET July 17, 2020 (MarketWatch)
Print

Shares of Nio Inc. (NIO) took a 6.8% dive in premarket trading Friday, after Goldman Sachs analyst Fei Fang turned bearish on the China-based electric vehicle maker, citing valuation concerns. He cut his rating to sell, after being at neutral since early October. His stock price target is $7, which is 46% below Thursday's closing price of $12.94. With the stock rising 89% over the past month, Fang wrote in a note to clients that he believes "the current share price reflects over-optimism given no substantial changes to volume/profit expectations (http://www.marketwatch.com/story/tesla-stock-rockets-higher-as-deliveries-crush-expectations-2020-07-02)." Over the long term, Fang said he believes Nio's investment case depends on the optionality for China's structural auto premiumization and EV adoption, combined with the scarcity of being China's first home-grown high-end passenger vehicle brand. The stock has more than tripled (up 222%) year to date through Thursday, while U.S.-based rival Tesla Inc. shares (TSLA) have nearly tripled (up 259%) and the S&P 500 has slipped 0.5%.

-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

July 17, 2020 09:14 ET (13:14 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.